SNMMI's mission with regard to health policy and regulatory affairs is to enhance its credibility, advance its issues, and through leadership become a valued partner among public policy stakeholders.
June 27, 2022 —
Aetna Reverses Cardiac PET/CT Non-Coverage & Updates Policy for PSMA Therapy
SNMMI and ASNC requested that Aetna reverse its non-coverage cardiac PET/CT policy. We are thrilled to communicate that within a few days of receiving our letter, Aetna reversed the policy. Also, Aetna recently updated and published their coverage policy for PSMA imaging for PLUVICTO therapy eligibility.
May 16, 2022 —
SNMMI & Partners Urge Congress to Support Increased Federal Research Funding
SNMMI and 368 members of the Ad Hoc Group for Medical Research sent a letter to Congress requesting that the Labor-HHS Subcommittee be allocated sufficient funding to allow for investment in NIH and other agencies that promote the health of our nation. The letter also urged Congress to work expeditiously to complete FY 2023 appropriations in a timely manner.
April 28, 2022 —
SNMMI and Partners Request a Hearing for the FIND Act
This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.
March 28, 2022 —
SNMMI Hosts AI and Patient Access Summits
On March 21-23, SNMMI hosted two summits in Bethesda, MD, on Artificial Intelligence and Barriers to Patient Access. The aim of the summits—the first of their kind for the society—was to bring together thought leaders to discuss current obstacles in the field of nuclear medicine and provide solutions. Read the highlights.
March 4, 2022 —
SNMMI Supports ARPA-H Act
SNMMI signed on as a supporting organization to the Advanced Research Project Agency Health (ARPA-H) Act and offered to be a resource as the bill's sponsor continues to refine the legislative text.